Cantharidin and Occlusion in Verruca Epithelium

Inclusion criteria

• ✓. Be healthy, immunocompetent males or females at least 2 years of age and older for Cohort 1 and 12 years of age and older for Cohort 2.
• ✓. Present with 1-6 common warts (verruca vulgaris) located anywhere on the body except for the following prohibited areas: the eye area (including eyelids), lips, oral cavity, nasal cavity, inside of the ears, palms of the hands, volar surface of the fingers or toes, under the finger nails (near and on the sides of the nails is allowed for Cohort 1, but warts near and on the sides of the nail (e.g., periungual) are not allowed in Cohort 2), soles of the feet, or the anogenital area. (Warts within 10 mm of a mucosal surface should not be treated).
• ✓. Have warts that are ≤10 mm in diameter and ≤3 mm in height. (Subjects with warts that are adjacent, touching or clustered may be included so long as the combined diameter in the longest direction does not exceed 10 mm. Individual lesions that are adjacent, touching or clustered should be counted as distinct lesions for the purposes of tracking, inclusion and clearance)(subjects in Cohort 2 can be pared, when necessary and appropriate, prior to evaluating height eligibility) .
• ✓. Have warts that have been present for at least 4 weeks at the time of the baseline visit.
• ✓. Consent to having all warts treated (the physician must also be willing to treat all warts initially present).
• ✓. Be otherwise medically healthy with no clinically significant medical history, physical examination or vital signs as determined by the investigator.
• ✓. Be free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of Aes.
• ✓. Refrain from swimming, bathing or prolonged immersion in water or any liquids until the Study drug is removed.

Exclusion criteria